The Strategy
AI-PPT: Fast-Tracking Drug Discovery
Drug discovery and development are traditionally costly and time-consuming, with the average new drug taking 13 years and $2.6 billion to reach approval. Sinoveda’s strategy aims to accelerate this process by leveraging time-tested remedies that have been effective for centuries. These natural formulations, while proven in traditional medicine, lack a scientific understanding of their active ingredients and mechanisms of action.
AI-PPT: Uncovering Active Ingredients and Mechanisms
Sinoveda’s AI-PPT technology addresses this knowledge gap by identifying, quantifying, and optimizing the active ingredients within these traditional remedies. Using systems and network pharmacology, AI-PPT decodes the mode of action of these compounds, dramatically increasing the chance of success for developing effective drug candidates.
Shortening Development Time and Increasing Success
AI-PPT also shortens development time by taking advantage of regulatory pathways. Candidates identified through AI-PPT can be introduced as consumer health products, allowing them to be tested in humans while clinical studies continue to confirm safety and efficacy. This offers two key advantages:
- Human Data Collection: Unlike preclinical candidates in conventional drug development, AI-PPT-derived candidates can gather valuable human data early on.
- Revenue Generation: Positive clinical outcomes not only validate the product’s efficacy but also enable progression through the clinical phase with a higher likelihood of success, reducing financial risk.
By fast-tracking drug development and increasing certainty of outcomes, AI-PPT presents a new paradigm in bringing safe, effective treatments to market faster and more affordably.
